Search
Brecanavir
go.drugbank.com/drugs/DB04887InvestigationalIn December of 2006 GSK announced a decision to discontinue the development of brecanavir for the treatment of HIV. The decision was based on issues regarding the formulation of the drug. … In July 2006, Vertex indicated that it expected GSK to initiate phase III trials of the drug in 2007.
Difluprednate
go.drugbank.com/drugs/DB06781ApprovedInvestigationalDifluprednate is a topical corticosteroid indicated for the treatment of infammation and pain associated with ocular surgery. It is a butyrate ester of 6(α), 9(α)-difluoro prednisolone acetate. … Difluprednate is abbreviated DFBA, or difluoroprednisolone butyrate acetate. It is indicated for treatment of endogenous anterior uveiti.
PH-284
go.drugbank.com/drugs/DB05452ExperimentalVomeropherins are self-administered by the patient with a metered nasal spray, or nasal aerosol device so that they can bind to peripheral chemosensory receptors in the nasal passages. … PH-284 is under investigation by Pherin and Organon for the treatment of anorexia nervosa, and loss of appetite and cachexia in cancer and AIDS patients.
Chlorfenson
go.drugbank.com/drugs/DB05377ExperimentalChlorfenson is developed by Moberg Derma for the treatment of onychomycosis (nail fungus) as the primary indication.
Dovitinib
go.drugbank.com/drugs/DB05928InvestigationalDovitinib is an orally active small molecule that exhibits potent inhibitory activity against multiple RTKs involved in tumor growth and angiogenesis. … Chiron currently has three ongoing Phase I clinical trials for dovitinib.
G17DT Immunogen
go.drugbank.com/drugs/DB04914InvestigationalIt is also in a phase II/III trial for advanced stomach cancer in combination with 5-fluorouracil and cisplatin and in a late phase II trial for advanced colorectal cancer in combination with irinotecan … It is in phase III trials for advanced pancreatic cancer as a monotherapy and in combination with gemcitabine.
Synonyms: G17DT (AN ANTIGASTRIN IMMUNOGEN)OMS-103HP
go.drugbank.com/drugs/DB05303InvestigationalOMS103HP is the first drug being developed to improve joint function following arthroscopic surgery, one of the most common procedures performed today by orthopedic surgeons.